Researchers at the University of Pennsylvania's Abramson Cancer Center found combining 2 immunotherapies to be safe and elicit a clinical response in patients with metastatic melanoma.
Researchers at the University of Pennsylvania’s Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug. The first-of-its-kind study found the dual treatments to be safe and elicit a clinical response in patients, according to new results from a phase I trial presented at the American Association for Cancer Research Annual Meeting 2015.
Researchers include first author David L. Bajor, MD, instructor of medicine in the division of hematology/oncology, and senior author Robert H. Vonderheide, MD, DPhil, the Hanna Wise Professor in Cancer Research.
“We’ve had wonderful success with immunotherapies, but we are barely scratching the surface,” Dr Bajor said.
Read the press release from Penn Medicine: http://bit.ly/1GbHx8d
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk
November 21st 2024Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.
Read More